Genscript Biotech Alerts Investors to Legend Biotech’s Q3-2026 Results Disclosure

Bulletin Express11-10

Genscript Biotech Corporation (Genscript) issued a voluntary announcement on 10 November 2026 to inform shareholders that its associate, Legend Biotech Corporation (Legend), has released financial results for the quarter ended 30 September 2026.

Legend, whose American Depositary Shares trade on the Nasdaq Global Select Market, submitted a Form 6-K to the U.S. Securities and Exchange Commission on the same day. The filing details Legend’s third-quarter 2026 financial performance and recent business developments.

Genscript emphasized that the disclosed figures relate solely to Legend and do not reflect Genscript’s own financial results. The Board advised shareholders and prospective investors to consider the inherent investment risks and to exercise caution when dealing in Genscript’s securities.

The complete Form 6-K is available on the SEC website at: https://www.sec.gov/Archives/edgar/data/1801198/000180119826000026/0001801198-26-000026-index.html.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment